Nestle flags further potential price hikes as tariffs, commodities weigh on margins

Nestle posted better-than-expected 2.9% organic sales growth in H1, fueled by 2.7% price hikes to counter record coffee and cocoa costs, though reported sales declined 1.8% and underlying trading operating profit margins dipped to 16.5%. CEO Laurent Freixe signaled potential further price increases in H2, while CFO Anna Manz warned of significantly lower H2 margins due to escalating input costs, tariffs, and FX headwinds, despite maintaining 2025 guidance. Concurrently, the new CEO is initiating a "fewer, bigger, better" strategy, including a review of underperforming vitamin brands, as Nestle shares declined 4.9%.

Analysis

Nestle's first-half results present a challenging operational picture despite beating organic sales growth estimates. The company achieved 2.9% organic growth, narrowly ahead of the 2.8% forecast, but this was entirely driven by aggressive pricing actions of 2.7% to combat historically high coffee and cocoa commodity costs. This pricing power, however, failed to protect overall financial performance, as total reported sales declined 1.8% to 44.2 billion Swiss francs, missing analyst expectations due to adverse foreign exchange effects from a strong Swiss franc. More critically, underlying trading operating profit margins contracted by 0.9% to 16.5%, and the outlook suggests further deterioration. The CFO issued a stark warning that second-half margins will be "significantly below the first half," as escalating input costs, U.S. tariffs, and FX headwinds are projected to more than offset the benefits of price hikes. This forecast triggered a 4.9% drop in Nestle's shares. In response to these pressures and a history of lagging peers like Unilever and Danone, new CEO Laurent Freixe is instituting a "fewer, bigger, better" strategy, focusing on six key product categories and initiating a strategic review of its underperforming vitamin brands for potential divestment. While the company maintained its 2025 guidance, the severe near-term margin warning creates significant uncertainty around its ability to navigate the current macroeconomic environment.

Key Decisions for Investors

• Given the explicit warning of significant margin compression in the second half, investors should anticipate continued share price volatility and scrutinize upcoming earnings for the full impact of input costs and tariffs.
• The success of the new CEO's 'fewer, bigger, better' strategy is now a critical catalyst; monitor progress on the six 'big bets' and the outcome of the vitamin brands' strategic review for signs of a successful turnaround.
• While Nestle has demonstrated pricing power, investors must watch for evidence of volume declines or market share loss to private labels, as further price increases on core products risk damaging consumer demand.
• The disconnect between the severe short-term margin warning and the maintained long-term 2025 guidance suggests a high degree of execution risk that should be factored into valuation models.